Armidex 1 - Canada Peptides

By the time anastrozole gained approval in 1995, it represented a critical advance over earlier anti-estrogens. Developed by Zeneca, the compound worked not by blocking estrogen, but by shutting down its biosynthesis via aromatase inhibition. This made it especially effective in postmenopausal breast cancer cases. The massive ATAC trial later confirmed its advantages, leading to widespread changes in treatment protocols. Its success in clinical settings also contributed to its later off-label use in hormonal regulation outside oncology.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Armidex 1 by Canada Peptides, consult with your doctor or healthcare professional.